Patents Represented by Attorney Ginger R. Dreger, Esq.

Find this attorney in the Justia Lawyer Directory

  • Serpentine transmembrane antigens expressed in human cancers and uses thereof
    Patent number: 7166714
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Grant
    Filed: December 31, 2003
    Date of Patent: January 23, 2007
    Assignee: Agensys, Inc.
    Inventors: Daniel E. H. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen C. Mitchell
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 6818746
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: November 16, 2004
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Luc Desnoyers, William I. Wood
  • Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same
    Patent number: 6812335
    Abstract: Human Edg4 and Edg5 polypeptides and their respective amino acid and nucleic acid sequences are provided for use in investigating cytoprotection, apoptosis, cellular proliferation, and other biological pathways in which phospholipid mediators are implicated.
    Type: Grant
    Filed: March 23, 1999
    Date of Patent: November 2, 2004
    Assignee: The Regents of the University of California
    Inventors: Edward Goetzl, Songzhu An
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 6767995
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: July 27, 2004
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Delivery of a composition to the liver by utilizing the portal vein
    Patent number: 6722370
    Abstract: In general, the invention features methods for delivering a composition to the liver in a non-surgical, percutaneous approach by utilizing the portal vein. Also disclosed are methods allowing for the liver-specific delivery of a composition.
    Type: Grant
    Filed: July 17, 1998
    Date of Patent: April 20, 2004
    Assignee: Corgentech, Inc.
    Inventor: Michael J. Mann
  • AL-2 neurotrophic factor nucleic acid
    Patent number: 6696557
    Abstract: The present invention provides nucleic acids encoding AL-2 protein, host cells and vectors containing these nucleic acids, and methods for their use to produce AL-2 protein by recombinant DNA methods.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: February 24, 2004
    Assignee: Genentech, Inc.
    Inventor: Ingrid W. Caras
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 6686451
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: February 3, 2004
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Jennie P. Mather, P. Mickey Williams, William I. Wood
  • Insulin-like growth factor agonist molecules
    Patent number: 6683053
    Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 27, 2004
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Henry B. Lowman, Iain C. A. F. Robinson
  • Rodent HER2 tumor model
    Patent number: 6632979
    Abstract: The invention concerns HER2-transgenic non-human mammals, animal models for screening drug candidates for the treatment of diseases and disorders associated with the overexpression of HER2. In particular, the invention concerns animal models designed to test drug candidates for the treatment of HER2-overexpressing cancers, including breast cancer, that are not responding or poorly responding to current treatments.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: October 14, 2003
    Assignee: Genentech, Inc.
    Inventors: Sharon Erickson, Kathleen King, Ralph Schwall
  • Process for making ice pops
    Patent number: 6610336
    Abstract: A process for making confection compositions such as ice pops of gel consistency, in the absence of heat treatment which takes advantage of a chemical reaction between an alginate salt, other than calcium alginate, or a low methoxy pectin and free calcium provides a homogeneous gel product which can be subsequently depositing into a mold pocket and converted into a desired product such as an ice pop by traditional steps.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: August 26, 2003
    Assignee: Ice Cream Partners USA, LLC
    Inventor: Mike Poorman
  • Neurotrophic factor
    Patent number: 6566091
    Abstract: A novel polypeptide, designated neurotrophic factor-4 (NT-4), has been identified by PCR amplification of human genomic DNA. Provided herein is nucleic acid encoding NT-4 useful in diagnostics and in the recombinant preparation of NT-4. Also provided herein are nucleic acids encoding naturally occurring amino acid sequence variants of NT-4, designated NT-4&bgr;, NT-4&ggr;, and NT-4&Dgr;. The neurotropic factors of the invention are useful in the treatment of nerve cells and in diagnostic assays.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: May 20, 2003
    Assignee: Genentech, Inc.
    Inventor: Arnon Rosenthal